Pfizer is ending two ongoing clinical studies for a Duchenne muscular dystrophy drug after determining that the evidence "did not support a significant treatment effect.”Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.